Imugene Ltd has released a press release.
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Imugene
- FDA Supports Strategy Toward Registration for Azer-cel
- Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
- Strategic Collaboration with JW Therapeutics
- S&P DJI Announces September 2025 Quarterly Rebalance
- Final Share Purchase Plan Allotment
Later from Imugene
- Half Yearly Report and Accounts
- Trading Halt
- 100% and 80% ORRs in Subset Indications in azer-cel study
- $20M placement and SPP, convertible notes amended
- Prospectus
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene